Hologic, Inc. [HOLX] stock is trading at $75.88, up 0.08%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The HOLX shares have gain 3.73% over the last week, with a monthly amount glided 1.57%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
On 1, February 2024, Hologic Announces First and Only FDA-Cleared Digital Cytology System – Genius™ Digital Diagnostics System. In a post published today on Yahoo Finance, Through a Combination of Advanced Imaging and Novel Artificial Intelligence, Latest Diagnostic System for Cervical Cancer Screening Can Help More Accurately Detect Disease, Improve Workflow and Enhance Patient Care.
From an analyst’s perspective:
Hologic, Inc. [NASDAQ: HOLX] stock has seen the most recent analyst activity on July 14, 2023, when Needham upgraded its rating to a Buy but kept the price target unchanged to $95 for it. Previously, RBC Capital Mkts started tracking the stock with Sector Perform rating on December 07, 2022, and set its price target to $75. On October 13, 2022, Mizuho initiated with a Buy rating and assigned a price target of $75 on the stock. UBS started tracking the stock assigning a Neutral rating and suggested a price target of $73 on July 20, 2022. BofA Securities downgraded its rating to a Neutral and reduced its price target to $75 on July 20, 2022. BTIG Research downgraded its rating to Neutral for this stock on July 18, 2022. In a note dated April 25, 2022, Wells Fargo downgraded an Equal Weight rating on this stock but restated the target price of $75.
Hologic, Inc. [HOLX] stock has fluctuated between $64.02 and $87.88 over the past year. Currently, Wall Street analysts expect the stock to reach $81.2 within the next 12 months. Hologic, Inc. [NASDAQ: HOLX] shares were valued at $75.88 at the most recent close of the market. An investor can expect a potential return of 7.01% based on the average HOLX price forecast.
Analyzing the HOLX fundamentals
Hologic, Inc. [NASDAQ:HOLX] reported sales of 3.97B for the trailing twelve months, which represents a drop of -5.69%. Gross Profit Margin for this corporation currently stands at -0.03% with Operating Profit Margin at -0.22%, Pretax Profit Margin comes in at -0.24%, and Net Profit Margin reading is -0.51%. To continue investigating profitability, this company’s Return on Assets is posted at -1.53, Equity is -2.61 and Total Capital is -22.65. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at -6.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 75.44 points at the first support level, and at 75.00 for the second support level. However, for the 1st resistance point, the stock is sitting at 76.41, and for the 2nd resistance point, it is at 76.94.
Hologic, Inc. [HOLX] reported earnings per share of $0.98 for its fiscal quarter that ended on 12/30/2023. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of $0.95/share, meaning a difference of $0.03 and a surprise factor of 3.20%. By comparison, the stated earnings for the previous quarter ended on 9/29/2023 were $0.89 per share as compared to estimates of $0.84 per share, a difference of $0.05 representing a surprise of 6.00%.
Ratios To Look Out For
For context, Hologic, Inc.’s Current Ratio is 3.89. Further, the Quick Ratio stands at 3.18, while the Cash Ratio is 0.05. Considering the valuation of this stock, the price to sales ratio is 4.49, the price to book ratio is 3.82 and price to earnings (TTM) ratio is 36.07.
Transactions by insiders
Recent insider trading involved Oberton Karleen Marie, Chief Financial Officer, that happened on Jan 29 when 14940.0 shares were sold. Director, Dockendorff Charles J completed a deal on Jan 02 to sell 16017.0 shares. Meanwhile, Director GARRETT SCOTT T sold 10000.0 shares on Dec 11.
